Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Modified Release Oxcarbazepine in Partial Epilepsy
NCT00391534Phase 3Terminated
- Sponsor
- Desitin Arzneimittel
- Start
- Oct 2006
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxcarbazepine in partial epilepsy (2 arms), sponsored by Desitin Arzneimittel. Primary endpoint: Maintenance dosage where dose up-titration has to be discontinued due to AEs at Day 26. Started Oct 2006; status: terminated.
02
Drugs
oxcarbazepine
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT00391534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391534.